A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Cancer; Neurofibromatoses
- Focus Adverse reactions; Therapeutic Use
- 04 Sep 2014 Planned End Date changed from 1 Mar 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 04 Sep 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 23 Sep 2013 Planned number of patients changed from 87 to 90 as reported by ClinicalTrials.gov.